Footnote
*CE marked for neurovascular access and removal/aspriation of emboli and thrombi from selected blood vessels in the neurovasculature. US FDA cleared to use in facilitating the insertion and guidance of microcatehters into selected blood vessels in the neurovasculature.
OUR COMPANY
Perfuze aims to improve patient outcomes with advanced superbore aspiration technology that simplifies access and clot removal.*
Footnote
Located in Galway City in the West of Ireland, Perfuze was co-founded in 2018 by experienced medtech innovators, Wayne Allen and Liam Mullins.